Senator Investment Group LP Invests $8.29 Million in Insmed Incorporated (NASDAQ:INSM)

Senator Investment Group LP bought a new position in Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 120,000 shares of the biopharmaceutical company's stock, valued at approximately $8,285,000. Senator Investment Group LP owned approximately 0.07% of Insmed as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC raised its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its stake in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed during the 4th quarter valued at about $47,000. Smartleaf Asset Management LLC grew its stake in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed in the fourth quarter worth approximately $86,000.

Insmed Price Performance

NASDAQ INSM traded up $0.73 on Friday, reaching $69.69. The company's stock had a trading volume of 13,610,728 shares, compared to its average volume of 2,298,330. The firm has a market cap of $12.67 billion, a PE ratio of -12.47 and a beta of 1.07. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The business has a 50-day moving average price of $74.61 and a 200 day moving average price of $73.55.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Sell-side analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 33,055 shares of the firm's stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $2,674,149.50. Following the completion of the sale, the insider now owns 138,053 shares in the company, valued at approximately $11,168,487.70. This trade represents a 19.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the transaction, the chief executive officer now owns 379,534 shares in the company, valued at $29,580,879.96. The trade was a 4.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 471,797 shares of company stock valued at $37,621,239 in the last three months. Corporate insiders own 3.00% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on INSM shares. Truist Financial lifted their target price on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a research note on Wednesday, March 19th. UBS Group increased their target price on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Wells Fargo & Company boosted their price target on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.